Emerald
Health Therapeutics Inc. ("Emerald" or “the Company”) (TSXV: EMH;
OTCQX: EMHTF) today announced that its joint venture, Emerald Health
Naturals (“EHN”), has received product licenses and natural product
numbers (NPNs) from Health Canada to sell its award-winning Endo product
line of endocannabinoid-supporting nutritional products in Canada. The
Endo product line has been designed to impact stress, anxiety, restless
sleep, pain and other conditions using non-cannabis ingredients. EHN
intends to launch the Endo product line over-the-counter in Canadian
natural health product, grocery, and pharmacy stores by mid-2019.
“Our
Endo product line was developed by internationally recognized natural
health product experts and is unique in the natural healthcare
marketplace. We are very excited to be able to offer our Endo products
to Canadian consumers to support their endocannabinoid systems and
improve aspects of their health,” said Dr. Gaetano Morello, CEO of EHN.
“We are leveraging our key strategic relationships and working hard on
the marketing, manufacturing and logistical steps in order to launch the
Endo line by mid-2019.”
The Endo product line
was developed by Emerald’s joint venture partner, San Diego-based
Emerald Health Bioceuticals, Inc. (“EHB”), and its scientific advisors.
Over the last year, EHB has secured multiple distribution and sales
channels in the United States and internationally for the Endo product
line, ranging from small independent natural health product retailers to
nation-wide grocery store chains and Amazon.com. EHN, which is owned
51% by Emerald and 49% by EHB, will have exclusive Canadian distribution
rights to the Endo products.
These
cannabis-free nutritional supplements feature PhytoCann-Complex™, a
proprietary formulation designed to support the body’s endocannabinoid
system, which plays a central role in the orchestration, maintenance,
and balance of health and well-being. The products include Endo SleepTM, Endo InflameTM, Endo BrainTM, Endo BlissTM, and Endo CalmTM.
Endo Brain was recently awarded a prestigious 2018 SupplySide Consumer
Packaged Goods Editor’s Choice Award for Brain Health, building on its
NEXTY "Editor's Choice" Best New Supplement Award in the natural
products industry in 2017.
“We have the unique
opportunity to brand Emerald through EHN’s offering of the Endo product
line through a number of valuable sales channels that are frequently
visited by cannabis users but which cannot currently sell cannabis
products,” said Dr. Avtar Dhillon, Executive Chairman and President of
Emerald. “In the event that CBD and other non-psychoactive cannabinoid
products are allowed to be sold in these channels in the future, Emerald
will be well positioned to add its cannabinoid compounds to the Endo
product line and leverage its early marketing advantage. Emerald’s
vision is to enhance human health through cannabis science. The creation
of EHN and the launch of the Endo product line in Canada are key steps
in Emerald’s strategy to achieve this goal.”
As
announced in the Company’s press release dated November 22, 2018, the
Company has obtained conditional approval of the TSX Venture Exchange
for the formation of the EHN joint venture. The parties are in the
process of finalizing definitive documentation with respect to EHN.
Formation of EHN is conditional upon final regulatory approval and
settlement of definitive documentation.
About the Endocannabinoid System
The
endocannabinoid system (“ECS”) is a biological system with a vital role
in regulating human health and disease. A lack of balance in the
endocannabinoid system is likely to have adverse consequences in a
number of human health conditions. The ECS is activated by
endocannabinoids produced naturally in the body, but also by cannabis or
non-cannabis plant ingredients that mimic the actions of cannabinoids
produced in the body. All products in the Endo product line contain
Phyto-CannTM Complex, which has been formulated by leading
nutritional and cannabinoid scientists with non-cannabis herbal and
botanical cannabinoids designed to favorably impact the ECS.
About Emerald Health Therapeutics
Emerald
Health Therapeutics, Inc. is a Canadian licensed producer of cannabis.
Its 50%-owned Pure Sunfarms joint venture in BC is completing the
conversion of its 1.1 million square feet (25 acres) greenhouse in the
Lower Mainland to cultivate cannabis and its Agro-Biotech operation in
Québec is currently operating out of its 75,000 square feet indoor
cannabis cultivation facility. Commercial production is expanding in
both facilities. In addition, Emerald has secured over 500 acres of hemp
harvest in 2018 and has contracted for approximately 1000 acres in 2019
to 2022, with the objective of extracting low-cost cannabidiol out of
its hemp harvest. Emerald’s team is highly experienced in life sciences,
product development, large-scale agri-business, and marketing, and is
focused on developing proprietary, value-added cannabis products for
medical and adult-use customers. Emerald, EHN and EHB are all part of
the Emerald Health group,
which represents a broad array of companies focused on developing
pharmaceutical, botanical, and nutraceutical products developed to
provide wellness and medical benefits by interacting with the human
body’s endocannabinoid system.
No comments:
Post a Comment